Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) PB Ratio : (As of May. 16, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Lixte Biotechnology Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-16), Lixte Biotechnology Holdings's share price is $2.38. Lixte Biotechnology Holdings's Book Value per Share for the quarter that ended in Mar. 2024 was $-0.17. Hence, Lixte Biotechnology Holdings's PB Ratio of today is .

The historical rank and industry rank for Lixte Biotechnology Holdings's PB Ratio or its related term are showing as below:

During the past 13 years, Lixte Biotechnology Holdings's highest PB Ratio was 215.14. The lowest was 0.00. And the median was 0.00.

LIXT's PB Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 2.54
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Lixte Biotechnology Holdings's average Book Value Per Share Growth Rate was -147.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -43.50% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Lixte Biotechnology Holdings was 54.20% per year. The lowest was -51.40% per year. And the median was 15.70% per year.

Back to Basics: PB Ratio

Lixte Biotechnology Holdings PB Ratio Historical Data

The historical data trend for Lixte Biotechnology Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings PB Ratio Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

PB Ratio

Get a 7-Day Free Trial

26.01

12.69

5.09

10.68

Lixte Biotechnology Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
PB Ratio	Get a 7-Day Free Trial															23.70	-	3.87	10.68	-

Competitive Comparison of Lixte Biotechnology Holdings's PB Ratio

For the Biotechnology subindustry, Lixte Biotechnology Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lixte Biotechnology Holdings's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's PB Ratio falls into.

Lixte Biotechnology Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Lixte Biotechnology Holdings's PB Ratio for today is calculated as follows:

PB Ratio	=	Share Price	/	Book Value per Share (Q: Mar. 2024)
	=	2.38	/	-0.166
	=

It can also be calculated from the numbers for the whole company:

PB Ratio

Market Cap

(Total Stockholders Equity

Preferred Stock)

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Lixte Biotechnology Holdings (NAS:LIXT) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.

Lixte Biotechnology Holdings PB Ratio Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXT) » Definitions » PB Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Executives

Rene Bernards	director	KONINGSVAREN 37, ABCOUDE P7 1391AD
Van Der Baan Bastiaan Jeroen	director	HOGEWEG 4-H, AMSTERDAM P7 1098CB
Eric Forman	10 percent owner	117 E. 29TH ST., APT. 5A, NEW YORK NY 10016
Regina Brown	director	248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Glenn Krinsky	10 percent owner	C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067
Yun Yen	director	1301 OAKLAWN ROAD, ARCADIA CA 91006
Robert Greenberg	10 percent owner	SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266
Gil Schwartzberg	10 percent owner	269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212
Philip F Palmedo	director	1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
John S Kovach	director, 10 percent owner, officer: Pres., CFO & Secty	1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
Stephen J. Forman	director	248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Hung Tak Ho	10 percent owner	MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000
Robert N Weingarten	officer: Vice President and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
James Miser	officer: Chief Medical Officer	680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101
Jane Merrill Riggs	10 percent owner	4852 SAINT ANDRES AVENUE, LA VERNE CA 91750